Swiss Rockets AG Appoints Prof. Dr. Andreas Türler as Chief Radiochemist

He will report to Dr. Nadezda Gracheva, Ph.D., Chief Operating Officer Nuclear Medicine, and contribute to projects focused on radioisotope production and the development of next-generation radioligand therapies (RLTs).

Prof. Dr. Türler is one of Europe’s most distinguished radiochemists and a globally recognized authority in radiopharmaceutical science. He is the author of 157 peer-reviewed scientific publications and has served for more than 15 years as Full Professor at the University of Bern and as Head of the Laboratory of Radiochemistry at the Paul Scherrer Institute (PSI).

In addition to his academic leadership, Prof. Dr. Türler has played a significant role in shaping national standards in radiation science and safety. Since 2013, he has served as Vice President of the Swiss Federal Commission for Radiation Protection and Monitoring of Radioactivity. Together with his team, he established a GMP-certified radiopharmacy at Insel University Hospital in Bern, supplying radiopharmaceuticals for diagnostic and therapeutic applications to multiple hospitals across Switzerland.

“Professor Türler brings exceptional scientific depth and hands-on GMP radiochemistry expertise to Torpedo,” said Dr. Nadezda Gracheva, Ph.D., Chief Operating Officer Nuclear Medicine at Torpedo Pharmaceuticals AG. “His experience in radioisotope production and clinical-grade radiopharmaceutical manufacturing will be instrumental as we advance our Terbium-161 programs and further strengthen our radioligand therapy platform.”
With this appointment, Torpedo Pharmaceuticals AG reinforces its commitment to scientific excellence and to building a fully integrated radiopharmaceutical development capability — from isotope production to clinical application.

About

Torpedo Pharmaceuticals AG is advancing next generation radioligand therapies to transform cancer treatment and improve patient outcomes. The innovative approach is built on Terbium-161, a groundbreaking medical radioisotope discovered through pioneering research at ETH Zurich by Dr. Nadezda Gracheva, who is the co-founding partner and Chief Operating Officer Nuclear Medicine at Swiss Rockets.

The lead target, 161Terbium-PSMA, has been preclinically characterized and is progressing well towards clinical development, holding significant promise for patients with prostate cancer. Leveraging Terbium-161, we are expanding our pipeline to develop radiopharmaceuticals targeting a range of solid tumors.
How it Works: 161Terbium-PSMA is intravenously administered, binding to PSMA receptors on prostate cancer cells. This targeted mechanism delivers localized radiation, effectively treating cancer while minimizing impact on healthy tissue.

https://torpedopharma.com/